
AbbVie (ABBV): Growth Momentum vs. Valuation Risk
AbbVie is delivering strong growth from Skyrizi, Rinvoq and neuroscience, but a rich valuation and heavy debt keep the stock in Hold territory.
Every article, report, and earnings note where ABBV appears.

AbbVie is delivering strong growth from Skyrizi, Rinvoq and neuroscience, but a rich valuation and heavy debt keep the stock in Hold territory.

TriGemX Bio is a clinical-stage biotech developing elismetrep for acute migraine, and it is going public through a merger with TCGX Acquisition Corp. The deal is expected to close in the first quarter of 2027, but the setup still hinges on redemptions, dilution, and whether Phase 3 execution stays on track.

Marc Lichtenfeld and The Oxford Club are promoting the Ultimate Dividend Package, a free bundle of five dividend-stock reports. We identify the best matches and test the income claims against filings.

A five-stock big pharma countdown spans vaccines, oncology, immunology and MedTech, featuring Amgen, Pfizer and Johnson & Johnson among diversified names.

Eli Lilly's next move looks less like a pipeline trade and more like an access trade. Demand was never the problem; broader PBM coverage and expected Medicare access starting July 1 make the revenue conversion story more immediate.

Healthcare’s leadership over tech and semis looks less like a defensive flinch and more like a valuation message from a still-hawkish market. With rates staying restrictive, investors are rewarding nearer-term earnings durability and demanding a higher bar for crowded long-duration growth.

AbbVie Inc. (ABBV) rises after announcing a $10.9 billion all-cash acquisition of Apogee Therapeutics. The deal expands AbbVie’s immunology pipeline and reinforces its post-Humira growth strategy, while strong recent earnings and raised guidance add support to the rally.

A seven-stock countdown spans beverages, restaurants, biopharmaceuticals and consumer staples, showing how dividend growth can blend income, defensiveness and earnings durability.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate ABBV ReportCancel anytime